Israel - hebreu - Ministry of Health

sanofi israel ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - תמיסה להזרקה - meningococcal vaccines group c 4 mcg / 0.5 ml; meningococcal vaccines group y 4 mcg / 0.5 ml; meningococcal vaccines group w 4 mcg / 0.5 ml; meningococcal vaccines group a 4 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - active immunization of individuals 9 mouths through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.

Israel - hebreu - Ministry of Health

sanofi israel ltd - aluminium hydroxide; diphtheria toxoid; tetanus toxoid - תרחיף להזרקה - diphtheria toxoid 2 iu / 0.5 ml; tetanus toxoid 20 iu / 0.5 ml; aluminium hydroxide 0.6 mg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - this vaccine is indicated for adults over 18 years of age in the following cases:- routine booster vaccinations against diphtheria and tetanus. the diphtheria toxoid content is reduced to one tenth of the normal dose to minimize the risks of a severe hypersensitivity reaction.- primary vaccination.- post-exposure prophylaxis following a tetanus-prone wound, if a booster diphtheria injection is required.this adsorbed diphtheria and tetanus vaccine may be administered as a booster vaccination in children over 10 years of age in whom poliomyelitis is prevented by separate administration of poliomyelitis vaccine.

Israel - hebreu - Ministry of Health

sanofi israel ltd - purified vi capsular polysaccharide of s.typhi - תמיסה להזרקה - purified vi capsular polysaccharide of s.typhi 0.025 mg / 0.5 ml - typhoid, purified polysaccharide antigen - typhoid, purified polysaccharide antigen - typhim vi vaccine is indicated for active immunization against typhoid fever for persons two years of age or older.

Israel - hebreu - Ministry of Health

sanofi israel ltd - hepatitis a vaccines - תרחיף להזרקה - hepatitis a vaccines 80 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - avaxim 80 u pediatric is indicated for active immunisation against infection caused by hepatitis a virus in children aged from 12 months to 15 years inclusive, who are at risk either of contaminating or spreading infection or of a life threatening disease if infected.

Israel - hebreu - Ministry of Health

sanofi israel ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תרחיף להזרקה - rabies, inactivated, whole virus 2.5 iu - rabies, inactivated, whole virus - rabies, inactivated, whole virus - prevention of rabies in children and adults. it can be used before and after exposure, as a primary vaccination or as a booster dose.

Israel - hebreu - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 3 years and over as a booster following primary immunisation . adacel polio is not indicatd for primary immunisation. adacel polio is not indicated for treating diseases caused by b. pertussis, c.diphtheriae or c. tetani or by poliomyelitis infections.

Israel - hebreu - Ministry of Health

sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Israel - hebreu - Ministry of Health

sanofi - aventis israel ltd - cabazitaxel 60 mg / 1.5 ml - concentrate for solution for infusion - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

Israel - hebreu - Ministry of Health

sanofi israel ltd - cabazitaxel - תרכיז וממס להכנת תמיסה לאינפוזיה - cabazitaxel 60 mg / 1.5 ml - cabazitaxel - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

Israel - hebreu - Ministry of Health

sanofi - aventis israel ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.